Supernus, Inc. SUPN
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About SUPN
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Supernus Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused primarily on developing and commercializing treatments for central nervous system (CNS) disorders. The company operates in the pharmaceutical and biotechnology industries, with a strategic emphasis on neurology and psychiatry. Its commercial portfolio includes products addressing epilepsy, attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease, migraine, and other neurological conditions. Revenue is primarily generated through branded prescription drug sales, supported by licensing arrangements and product commercialization activities.
The company’s principal commercial products have included Qelbree for ADHD, Gocovri for Parkinson’s disease dyskinesia, and ApoKyn for advanced Parkinson’s disease management, alongside legacy epilepsy products such as Trokendi XR and Oxtellar XR. Supernus has positioned itself around specialized CNS therapies with a focus on differentiated formulations, targeted physician engagement, and lifecycle management of neurological products. Founded in 2005 and headquartered in Rockville, Maryland, the company expanded from formulation-based epilepsy treatments into broader CNS therapeutics through internal development and acquisitions, including the acquisition of Adamas Pharmaceuticals in 2021.
Business Operations
Supernus organizes its business primarily around branded CNS pharmaceutical products and product development programs. Its commercial operations focus on marketed prescription therapies within neurology and psychiatry, while its research and development efforts target movement disorders, epilepsy, depression, and other CNS-related indications. Revenue is generated predominantly from U.S. pharmaceutical sales through specialty pharmacies, wholesalers, and healthcare providers. The company has historically relied heavily on the U.S. market, although certain products and intellectual property arrangements have involved international licensing and distribution relationships.
The company controls several proprietary drug formulations, extended-release delivery technologies, and intellectual property assets supporting marketed and pipeline therapies. Key operating assets include the commercial brands Qelbree, Gocovri, ApoKyn, Trokendi XR, and Oxtellar XR. Supernus has also maintained partnerships related to product distribution, manufacturing, and licensing arrangements. The acquisition of Adamas Pharmaceuticals significantly expanded its movement disorder portfolio and strengthened its presence in Parkinson’s disease treatment markets.
Strategic Position & Investments
Supernus has pursued a strategy centered on expanding its CNS portfolio through acquisitions, lifecycle management, and internal drug development. A major strategic milestone was the acquisition of Adamas Pharmaceuticals, which added Parkinson’s disease therapies and broadened the company’s neurological franchise. The company has also invested in pipeline development programs targeting depression, epilepsy, and other neuropsychiatric conditions, while continuing commercialization efforts for ADHD treatment Qelbree, viewed as a long-term growth driver.
The company’s strategic direction reflects an emphasis on specialty CNS therapeutics with relatively concentrated physician audiences and high unmet medical need. Supernus has invested in clinical-stage assets and intellectual property intended to extend product exclusivity and support future revenue diversification. Its development activities have included exploration of novel formulations and expanded indications for existing therapies. Public filings and investor materials indicate continued focus on balancing commercial-stage revenue generation with selective investment in late-stage CNS development opportunities.
Geographic Footprint
Supernus is headquartered in Rockville, Maryland, and its primary commercial operations are concentrated in the United States. The company markets its key prescription products mainly through the U.S. healthcare system, including specialty pharmacies, wholesalers, neurologists, psychiatrists, and other specialist prescribers. While its direct international commercial presence is limited compared with larger multinational pharmaceutical companies, the company has maintained certain international licensing and intellectual property relationships.
The company’s operational influence is strongest in the North American CNS pharmaceutical market, particularly within neurology and psychiatry specialty segments. Manufacturing and supply-chain activities involve third-party partners that may operate across multiple global regions. Supernus also participates indirectly in international pharmaceutical markets through patents, licensing agreements, and supply arrangements associated with certain products and technologies.
Leadership & Governance
Supernus was founded by neurologist and pharmaceutical executive Jack A. Khattar, who has played a central role in shaping the company’s CNS-focused strategy and commercial expansion. The company’s leadership philosophy has emphasized disciplined specialty pharmaceutical growth, targeted acquisitions, and investment in differentiated neurological therapies. Governance oversight is provided through its executive leadership team and board of directors, with strategic focus on commercial execution, pipeline advancement, and shareholder value creation.
Key executives include:
- Jack A. Khattar – President and Chief Executive Officer
- Gregory S. Patrick – Senior Vice President and Chief Financial Officer
- Ritu Baral – Vice President, Corporate Development and Investor Relations
- Padmanabh P. Bhatt – Senior Vice President, Intellectual Property and Chief Scientific Officer
- Jonathan Rubin – Senior Vice President, General Counsel and Corporate Secretary
The company’s leadership structure reflects a blend of pharmaceutical commercialization, CNS research, intellectual property management, and specialty drug development expertise. Public disclosures, including SEC filings and investor presentations, indicate that management continues to prioritize expansion of the CNS portfolio and optimization of commercial assets through targeted operational execution.